Introduction {#s1}
============

Autoimmune thyroid disease (AITD), including Hashimoto\'s thyroiditis and Graves\' disease, is one of the most common autoimmune diseases, affecting 2--5% of the general population [@pgen.1004123-Gough1], [@pgen.1004123-Simmonds1], [@pgen.1004123-Tunbridge1]. Thyroid dysfunction has been associated with osteoporosis, depression, atrial fibrillation, heart failure, metabolic syndrome, and mortality [@pgen.1004123-Biondi1], [@pgen.1004123-Collet1], [@pgen.1004123-Davis1], [@pgen.1004123-Gencer1], [@pgen.1004123-Nicholls1], [@pgen.1004123-Rodondi1], [@pgen.1004123-Ruhla1], [@pgen.1004123-Selmer1]. High serum antibodies against the enzyme thyroid peroxidase (TPO), which is located in the thyroid and plays a key role in thyroid hormone synthesis, are present in 90% of patients with Hashimoto\'s thyroiditis [@pgen.1004123-Pearce1], [@pgen.1004123-Schweizer1], the most frequent cause of hypothyroidism and goiter. Although TPO antibodies (TPOAbs) are a useful clinical marker for the detection of early AITD, it remains controversial if these antibodies play a causative role in the pathogenesis of Hashimoto\'s thyroiditis [@pgen.1004123-Brix1], [@pgen.1004123-Huber1], [@pgen.1004123-Nielsen1].

Interestingly, TPOAb-positive persons also have an increased risk of developing autoimmune hyperthyroidism (Graves\' disease) [@pgen.1004123-Strieder1], [@pgen.1004123-Strieder2], which is caused by stimulating antibodies against the thyroid stimulating hormone (TSH) receptor [@pgen.1004123-Weetman1]. Numerous studies have shown that Graves\' hyperthyroidism and Hashimoto\'s thyroiditis show co-inheritance [@pgen.1004123-Strieder1], [@pgen.1004123-Brix2], [@pgen.1004123-Tomer1]. Finally, thyroid autoimmunity is the most common autoimmune disorder in women of childbearing age, and TPOAb-positive women have an increased risk of developing pregnancy complications such as miscarriage and pre-term delivery [@pgen.1004123-Strieder1], [@pgen.1004123-Strieder2], [@pgen.1004123-Kordonouri1], [@pgen.1004123-Medici1], [@pgen.1004123-Negro1], [@pgen.1004123-Poppe1], [@pgen.1004123-Vanderpump1].

The prevalence of TPOAb-positivity in the general population ranges from 5--24%, but it is currently unknown why these people develop TPOAbs, nor is it known why not all individuals with thyroid autoimmunity develop clinical thyroid disease [@pgen.1004123-Hollowell1], [@pgen.1004123-Weetman2]. It is estimated that around 70% of the susceptibility to develop thyroid autoantibodies is due to genetic factors [@pgen.1004123-Hansen1]. In this context it is remarkable to note that little is known about the genetic factors that determine TPOAb-positivity and the risk of AITD.

We therefore performed a genome wide association study (GWAS) meta-analysis for TPOAbs in the general population in 18,297 individuals from 11 populations. Newly identified genetic variants were studied in relation to subclinical and overt hypo- and hyperthyroidism, goiter, thyroid autoimmunity during pregnancy and thyroid cancer risk.

Results {#s2}
=======

Characteristics of the studied populations are shown in [Table 1](#pgen-1004123-t001){ref-type="table"} and the Supplementary Material S1. Heritability estimates in the family-based cohorts SardiNIA, TwinsUK and Val Borbera were, respectively, 0.65, 0.66, and 0.54 for TPOAb-positivity, and 0.43, 0.66, and 0.30 for TPOAb levels.

10.1371/journal.pgen.1004123.t001

###### Population characteristics and serum TPOAb, TSH, and FT4 level measurements specifications.

![](pgen.1004123.t001){#pgen-1004123-t001-1}

                                          Sample characteristics   TPOAb specifications   TSH specifications   FT4 specifications                                                                                                                                                                                                          
  ------------ ------------------------- ------------------------ ---------------------- -------------------- -------------------- ----- ------------- ------- ----------- -------------------------------------------------------- -------------------- ------------------------------------------------------------- ------------------- -------------------------------------------------------------
  Stage 1                                                                                                                                                                                                                                                                                                                                  
  BHS            Caucasian (Australia)             1363                     47             1316 (197/1119)            1316          43%   53.0 (17.2)   15.0%      35        Immulite 2000 chemiluminescent immunoassay (5-5000)     1.3 (0.9;1.9) mU/L   Immulite 2000 chemiluminescent immunoassay (0.4 - 4.0 mU/L)   16.9 (2.5) pmol/L   Immulite 2000 chemiluminescent immunoassay (9 -- 23 pmol/L)
  CHS               Caucasian (USA)                2024                     0              2024 (281/1743)            1817          41%   74.8 (5.1)    13.9%      34               Chemiluminescent immunoassay (5--600)            2.3 (1.5;3.5) mU/L          Chemiluminescent immunoassay (0.27--4.2 mU/L)           1.2 (0.2) ng/dL          Chemiluminescent immunoassay (0.93--1.7 ng/dL)
  HBCS            Caucasian (Finland)              526                      29               497 (75/422)             497           50%   61.0 (2.8)    15.1%      12               Chemiluminescent immunoassay (0--1000)           2.0 (1.2;2.4) mU/L         Chemiluminescent immunoassay (0.49--4.67 mU/L)          14.1 (1.6) ng/dL          Chemiluminescent immunoassay (0.71--1.85 ng/dL)
  KORA            Caucasian (Germany)              1765                     49              1475 (74/1401)            1475          45%   60.5 (8.9)    5.0%       200              Chemiluminescent immunoassay (1--3000)           1.5 (0.6;2.5) mU/L          Chemiluminescent immunoassay (0.4--4.3 mU/L)           18.9 (2.6) pmol/L          Chemiluminescent immunoassay (11--25 pmol/L)
  NBS           Caucasian (Netherlands)            1829                     26             1829 (287/1542)            1829          50%   61.5 (10.3)   15.7%      12               Fluoro-immunometric assay (2.6--1000)            1.3 (0.9;2.0) mU/L            Immuno-luminometric assay (0.4--4.0 mU/L)            13.5 (2.4) pmol/L         Chemiluminescent immunoassay (8.0--22.0 pmol/L)
  RS            Caucasian (Netherlands)            1627                     50             1577 (137/1440)            210           40%   70.2 (5.6)    8.7%       35               Chemiluminescent immunoassay (5--5000)           1.2 (0.6:2.5) mU/L          Chemiluminescent immunoassay (0.4--4.3 mU/L)           18.4 (2.4) pmol/L          Chemiluminescent immunoassay (11--25 pmol/L)
  SardiNIA         Caucasian (Italy)               4686                    154              972 (108/864)             1257          49%   56.9 (12.5)   11.1%      35               Chemiluminescent immunoassay (5--1000)           1.3 (0.8:2.0)mU/L           Chemiluminescent immunoassay (0.4--4.0 mU/L)            1.3 (0.2) ng/dL           Chemiluminescent immunoassay (0.3--2.4 ng/dl)
  SHIP            Caucasian (Germany)              4096                    293             3803 (265/3538)            1818          52%   49.3 (16.3)   7.0%       60               Chemiluminescent immunoassay (1--3000)           0.7 (0.4;1.0) mU/L          Chemiluminescent immunoassay (0.3--3.0 mU/L)           12.8 (3.8) pmol/L        Chemiluminescent immunoassay (7.7-- 23.2 pmol/L)
  SHIP-Trend      Caucasian (Germany)              986                      99               887 (36/851)             887           46%   49.5 (13.7)   4.1%       200              Chemiluminescent immunoassay (1--3000)           1.2 (0.8;1.6) mU/L         Chemiluminescent immunoassay (0.36--3.74 mU/L)                 \-                                       \-
  TwinsUK           Caucasian (UK)                 2455                     86             2369 (461/1893)            774           0%    46.9 (12.5)   19.5%       6              Chemiluminescent immunoassay (0.5--1000)          1.3 (0.9;1.8) mU/L           Chemiluminescent immunoassay0.4--4.0 mU/L)            13.6 (1.9) pmol/L           Chemiluminescent immunoassay (9--19 pmol/L)
  ValBorbera       Caucasian (Italy)               1661                     90             1571 (161/1410)            452           46%   54.3 (18.4)   10.2%   60 and 50   Two chemiluminescent immunoassays (5.5--3000 ; 6-7500)   1.4 (0.9;2.0) mU/L         Chemiluminescent immunoassay (0.34--5.60 mU/L)                 \-                                       \-

                                            Sample characteristics   TPOAb specifications   TSH specifications   FT4 specifications                                                                                                                                                                        
  ------------------ --------------------- ------------------------ ---------------------- -------------------- -------------------- ----- ------------- ------- ----- ---------------------------------------- ---------------------- ----------------------------------------------- ------------------- --------------------------------------------------
  Stage 2                                                                                                                                                                                                                                                                                                  
  Asklepios           Caucasian (Belgium)            2418                    109             2309 (245/2064)            2185          50%   45.9 (5.9)    10.6%   35    Chemiluminescent immunoassay (5--600)     1.5 (1.1;2.1) mU/L    Chemiluminescent immunoassay (0.3--4.2 mU/L)    1.31 (0.2) ng/dL     Chemiluminescent immunoassay (0.9--1.7 ng/dl)
  CARLA               Caucasian (Germany)            1753                    270             1483 (186/1297)            1190          60%   64.2 (10.2)   12.5%   28    Chemiluminescent immunoassay (5--600)     0.9 (0.6;1.2) mU/L    Chemiluminescent immunoassay (0.4-- 3.8 mU/L)   16.3 (2.5) pmol/L   Chemiluminescent immunoassay (12.8--20.4 pmol/L)
  EFSOCH                Caucasian (UK)               1289                     \-              1289 (97/1192)            1233          64%   34.2 (5.9)    7.5%    34    Chemiluminescent immunoassay (5--600)     1.9 (1.3;2.6) mU/L    Chemiluminescent immunoassay (0.4--4.5 mU/L)    16.0 (2.4) pmol/L     Chemiluminescent immunoassay (11--24 pmol/L)
  Health2006 Study    Caucasian (Danish)             3287                     \-             3287 (204/3083)            3285          45%   49.3 (13.0)   6.2%    100   Chemiluminescent immunoassay (1--3000)    1.7 (1.0;2.0) mU/L    Chemiluminescent immunoassay (0.4--3.7 mIU/L)   12.4 (1.8) pmol/L   Chemiluminescent immunoassay (9.8--18.8 pmol/L)
  SardiNIA2            Caucasian (Italy)             1387                     30              765 (104/661)             375           41%   46.6 (17.4)   13.6%   35    Chemiluminescent immunoassay (5--1000)   1.6 (1.0;2.2) mIU/ml   Chemiluminescent immunoassay (0.4-- 4.0 mU/L)    1.3 (0.2) ng/dl     Chemiluminescent immunoassay (0.3--2.4 ng/dl)

Loci associated with TPOAb-positivity and TPOAb levels {#s2a}
------------------------------------------------------

See [Table 1](#pgen-1004123-t001){ref-type="table"} and Supplementary [Figure S1](#pgen.1004123.s001){ref-type="supplementary-material"} for TPOAb measurements and Supplementary [Table S1](#pgen.1004123.s007){ref-type="supplementary-material"} for genotyping procedures. In most autoimmune diseases, both the presence and the level of autoantibodies are relevant for the disease onset [@pgen.1004123-Strieder2], [@pgen.1004123-Linnik1], [@pgen.1004123-Nielsen2]. Furthermore, different pathophysiological processes may be involved in the initiation and severity of the autoimmune response. We therefore performed a GWAS on TPOAb-positivity (including 1769 TPOAb-positives and 16,528 TPOAb--negatives), as well as a GWAS on continuous TPOAb levels (including 12,353 individuals) in stage 1. See Supplementary [Figures S2](#pgen.1004123.s002){ref-type="supplementary-material"} and [S3](#pgen.1004123.s003){ref-type="supplementary-material"} for QQ (quantile-quantile) and Manhattan plots.

In stage 2, we followed-up 20 stage 1 SNPs (*P*\<5×10^−6^; 13 TPOAb-positivity and 10 TPOAb level SNPs, with 3 SNPs overlapping) in 5 populations, including up to 8,990 individuals for TPOAb-positivity (922 TPOAb-positives and 8068 TPOAb--negatives) and 8,159 individuals for TPOAb level analyses (see Supplementary Material S1). Results of the combined stage 1 and 2 meta-analyses, including heterogeneity analyses, are shown in Supplementary [Tables S2](#pgen.1004123.s008){ref-type="supplementary-material"} and [S3](#pgen.1004123.s009){ref-type="supplementary-material"}. Regional association plots are shown in Supplementary [Figures S4](#pgen.1004123.s004){ref-type="supplementary-material"} and [S5](#pgen.1004123.s005){ref-type="supplementary-material"}. In the combined stage 1 and 2 meta-analyses GWAS significant associations (*P*\<5×10^−8^) were observed near *TPO* (Chr 2p25; rs11675434), at *ATXN2* (Chr 12q24.1; rs653178), and *BACH2* (Chr 6q15; rs10944479) for TPOAb-positivity, and near *TPO* (rs11675434), at *MAGI3* (Chr 6q15; rs1230666), and *KALRN* (Chr 3q21; rs2010099) for TPOAb levels ([Table 2](#pgen-1004123-t002){ref-type="table"} and [Figure 1](#pgen-1004123-g001){ref-type="fig"}). The TPOAb level meta-analysis *P*-values for the 3 GWAS significant TPOAb-positivity loci were: *TPO*-rs11675434: *P* = 7.4×10^−13,\ *ATXN2*^-rs653178: *P* = 1.3×10^−7,\ and^ *BACH2-*rs10944479: *P* = 2.0×10^−4.^

![Genome wide association studies meta-analyses: Loci associated with TPOAb-positivity (a--c) and TPOAb levels (d--f) on a genome-wide level of significance.\
Regional association plots of the genome-wide significant loci associated with TPOAb positivity (a--c) and TPOAb levels (d--f). The y-axis on the left indicates the -- log~10~ *P* value for the association with TPOAb --positivity (a--c) or TPOAb levels (d--f). SNPs are plotted on the x-axis according to their chromosomal position against the association with the phenotype on the y-axis. The most significant stage 1 SNP is indicated in purple. The combined stage 1 and 2 result of this SNP is indicated in yellow. The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP. Symbols reflect functional genomic annotation, as indicated in the legend. The blue y-axes on the right of each plot indicate the estimated recombination rates (based on HapMap Phase II); the bottom of each panel shows the respective annotated genes at the locus and their transcriptional direction. Mb, megabases.](pgen.1004123.g001){#pgen-1004123-g001}
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###### Newly identified loci associated with TPOAb-positivity and/or serum TPOAb levels reaching genome wide significance.

![](pgen.1004123.t002){#pgen-1004123-t002-2}

                                                                  Alleles                                                 Stage 1 + 2 meta-analysis: up to 2691 cases and 24,596 controls                                                
  -------------------- ------------ ------ --------------------- --------- ------- ------------------------------------- ----------------------------------------------------------------- --------------------------------------------- -------------
  *TPOAb-positivity*       SNP       Chr.   Position (Build 36)    Risk     Other   RAF[a](#nt102){ref-type="table-fn"}                             Nearby gene                             OR (95% CI)[b](#nt103){ref-type="table-fn"}    *P* value
                        rs11675434    2           1386822            T        C                    0.39                                                *TPO*                                             1.21 (1.15--1.28)                1.5×10^−16^
                         rs653178     12         110492139           C        T                    0.40                                               *ATXN2*                                            1.14 (1.08--1.19)                9.9×10^−10^
                        rs10944479    6          90937114            A        G                    0.16                                               *BACH2*                                            1.25 (1.14--1.37)                4.0×10^−8^
                                                                  Alleles                                                        Stage 1 + 2 meta-analysis: up to 20,512 subjects                                                        
  *TPOAb levels*           SNP       Chr.   Position (Build 36)    Risk     Other   RAF[a](#nt102){ref-type="table-fn"}                             Nearby gene                              *β* (SE)[c](#nt104){ref-type="table-fn"}      *P* value
                        rs11675434    2           1386822            T        C                    0.39                                                *TPO*                                              0.0202 (0.0046)                 7.4×10^−13^
                        rs1230666     1          113974933           A        G                    0.16                                               *MAGI3*                                             0.0269 (0.0064)                 1.8×10^−8^
                        rs2010099     3          125782947           C        T                    0.91                                               *KALRN*                                             0.0240 (0.0076)                 3.1×10^−8^

Chr., chromosome

Risk allele frequency: Weighted mean frequency of the risk allele across all included cohorts.

Adjusted for age and gender

Expressed in sd of natural logarithm transformed serum TPOAb level, adjusted for age and gender

As the 3 GWAS significant loci for TPOAb levels also showed associations with TPOAb-positivity (*TPO*-rs11675434*:* OR, 1.21 \[95% CI, 1.15--1.28)\], *P* = 1.5×10^−16^; *MAGI3*-rs1230666*:* OR, 1.23 \[95% CI, 1.14--1.33\], *P* = 1.5×10^−6^; *KALRN*-rs2010099*:* OR, 1.24 \[95% CI, 1.12--1.37\], *P* = 7.4×10^−5^), we subsequently studied the (combined) effects of these 5 SNPs on clinical thyroid disease. Genetic risk scores were calculated as described in the Supplementary Material. The variance explained by these 5 SNPs was 3.1% for TPOAb-positivity and 3.2% for TPOAb levels. Subjects with a high genetic risk score had a 2.2 times increased risk of TPOAb-positivity compared to subjects with a low genetic risk score (*P* = 8.1×10^−8^) ([Table 3](#pgen-1004123-t003){ref-type="table"}).

10.1371/journal.pgen.1004123.t003

###### Genetic risk score and the risk of TPOAb-positivity.

![](pgen.1004123.t003){#pgen-1004123-t003-3}

  GRS Quartile     \% TPOAb-positivity (N cases/total)   OR (95% CI)[a](#nt106){ref-type="table-fn"}   *P* value
  --------------- ------------------------------------- --------------------------------------------- ------------
  1 (reference)              5.4% (89/1637)                                  \-                            \-
  2                          7.0% (114/1637)                          1.29 (0.98--1.69)                   0.07
  3                          9.0% (152/1695)                          1.64 (1.26--2.13)                1.3×10^−4^
  4                         10.4% (158/1523)                          2.18 (1.68--2.81)                8.1×10^−8^

GRS, genetic risk score (based on rs11675434, rs653178, rs10944479, rs1230666, rs2010099).

Adjusted for age and gender

[Table S4](#pgen.1004123.s010){ref-type="supplementary-material"} shows the stage 1 TPOAb-positivity and TPOAb level meta-analyses results for GWAS significant SNPs reported in previous GWAS on thyroid related phenotypes.

Associations with hypo- and hyperthyroidism {#s2b}
-------------------------------------------

The associations between the 5 GWAS significant SNPs and the risk of abnormal thyroid function tests are shown in [Table 4](#pgen-1004123-t004){ref-type="table"}. *MAGI3*- rs1230666 was associated with an increased risk of overt hypothyroidism and increased TSH levels below the Bonferroni threshold (i.e., *P = *0.05/5 = 0.01). Borderline significant signals were observed at *BACH2*- rs10944479 with a higher risk of increased TSH levels as well as overt hyperthyroidism (*P = *0.011 and *P = *0.012), and at the *KALRN*-rs2010099 SNP with a lower risk of decreased TSH levels (*P = *0.010).

10.1371/journal.pgen.1004123.t004

###### Newly identified TPOAb associated loci and the risk of thyroid disease in stage 1 and 2 populations.
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                          Alleles   Increased TSH (1110 cases/19,189 controls)   Hypothyroidism (173 cases/15,940 controls)   Decreased TSH (967 cases/19,297 controls)   Hyperthyroidism (78 cases/14,901 controls)                                                               
  --------- ------------ --------- -------------------------------------------- -------------------------------------------- ------------------------------------------- -------------------------------------------- ------------ ------------------- ------- ------------------- -------
  *TPO*      rs11675434      T                          C                                    1.08 (0.99--1.18)                                  0.08                                  1.14 (0.91--1.42)                   0.26      1.02 (0.93--1.11)   0.68    1.10 (0.81--1.49)   0.54
  *ATXN2*     rs653178       C                          T                                    1.01 (0.98--1.04)                                  0.68                                  1.25 (1.01--1.54)                   0.04      1.01 (0.97--1.04)   0.70    1.00 (0.74--1.33)   0.99
  *BACH2*    rs10944479      A                          G                                    1.17 (1.04--1.32)                                  0.011                                 1.37 (1.00--1.88)                   0.05      0.91 (0.80--1.03)   0.15    1.80 (1.14--2.85)   0.012
  *MAGI3*    rs1230666       A                          G                                    1.23 (1.09--1.39)                               9.0×10^−4^                               1.57 (1.18--2.10)                1.9×10^−3^   1.08 (0.96--1.22)   0.22    1.61 (0.99--2.60)   0.05
  *KALRN*    rs2010099       C                          T                                    1.05 (0.90--1.23)                                  0.52                                  0.80 (0.54--1.20)                   0.28      0.82(0.71--0.95)    0.010   0.69 (0.39--1.24)   0.21

All analyses adjusted for age and gender.

*ATXN2*-rs653178 is in high LD with *SH2B3-* rs3184504

*MAGI3-*rs1230666 is in high LD with *PTPN22-*rs2476601

Furthermore, a higher genetic risk score was associated with a higher risk of increased TSH levels (Supplementary [Table S5](#pgen.1004123.s011){ref-type="supplementary-material"}). No effects of the genetic risk score on the risk of overt hypothyroidism, hyperthyroidism or decreased TSH levels were observed.

Associations with goiter {#s2c}
------------------------

Individuals with a high genetic risk score had a 30.4% risk of sonographically-proven goiter, compared to 35.2% in subjects with a low score (*P* = 6.5×10^−4^) ([Table 5](#pgen-1004123-t005){ref-type="table"}). None of the individual SNPs was significantly associated with goiter risk.

10.1371/journal.pgen.1004123.t005

###### Newly identified TPOAb associated loci, genetic risk scores and the risk of goiter.

![](pgen.1004123.t005){#pgen-1004123-t005-5}

  --------- ------------ --- --- ------------------- ------ --------------- ------------------ ------------------- ------------
  *TPO*      rs11675434   T   C   0.95 (0.88--1.02)   0.17   1 (reference)   35.2% (588/1669)          \-               \-
  *ATXN2*     rs653178    C   T   0.95 (0.88--1.03)   0.22         2         33.7% (570/1691)   0.92 (0.79--1.06)      0.21
  *BACH2*    rs10944479   A   G   0.94 (0.85--1.05)   0.28         3         31.6% (530/1675)   0.84 (0.72--0.98)      0.03
  *MAGI3*    rs1230666    A   G   0.90 (0.81--1.00)   0.05         4         30.4% (517/1702)   0.77 (0.66--0.89)   6.5×10^−4^
  *KALRN*    rs2010099    C   T   0.93 (0.81--1.05)   0.23                                                         
  --------- ------------ --- --- ------------------- ------ --------------- ------------------ ------------------- ------------

GRS, genetic risk score (based on rs11675434, rs653178, rs10944479, rs1230666, rs2010099).

Adjusted for age, gender, and body surface area.

*ATXN2*-rs653178 is in high LD with *SH2B3*-rs3184504.

*MAGI3*-rs1230666 is in high LD with *PTPN22*-rs24756601.

Thyroid autoimmunity during pregnancy {#s2d}
-------------------------------------

As autoimmunity significantly changes during pregnancy [@pgen.1004123-Poppe1], we additionally studied these effects in an independent pregnant population. Pregnant women with a high genetic risk score had a 2.4 times increased risk of TPOAb-positivity compared to women with a low score (10.3% vs 4.8%, *P* = 0.03). These women did not have a higher risk of increased TSH levels. However, a borderline significant signal with a lower risk of increased TSH levels was observed at *ATXN2*- rs653178 (OR, 0.54 \[95% CI, 0.34--0.87\], *P* = 0.012).

Associations with thyroid disease in independent populations {#s2e}
------------------------------------------------------------

### a) Graves\' disease {#s2e1}

As *MAGI3*- rs1230666 and *BACH2*- rs10944479 showed promising associations (i.e., *P*≤0.05) with hyperthyroidism in our meta-analyses, we tested these SNPs in an independent population of 2478 patients with Graves\' disease and 2682 controls (see Supplementary Material for further details). Both were associated with an increased risk of Graves\' disease (*MAGI3*- rs1230666: OR, 1.37 \[95% CI, 1.22--1.54\]; *P* = 1.2×10^−7;^ *BACH2*- rs10944479: OR, 1.25 \[1.12--1.39\]; *P* = 6.2×10^−5^).

### b) Thyroid cancer {#s2e2}

Supplementary [Table S6](#pgen.1004123.s012){ref-type="supplementary-material"} shows the associations of the 5 GWAS significant SNPs with thyroid cancer. No statistically significant associations were detected, but a borderline significant signal with an increased risk of thyroid cancer was observed at *ATXN2*- rs653178 (OR, 1.32 \[95% CI, 1.02--1.70\], *P* = 0.03).

Pathway analyses {#s2f}
----------------

Ingenuity Pathway Analyses (IPA; Ingenuity Systems, Ca, USA) and GRAIL analyses [@pgen.1004123-Raychaudhuri1] were performed to identify potential pathways involved in AITD, the results of which are shown in Supplementary [Tables S7](#pgen.1004123.s013){ref-type="supplementary-material"} and [S8](#pgen.1004123.s014){ref-type="supplementary-material"}, and [Figure S6](#pgen.1004123.s006){ref-type="supplementary-material"}. The identified top pathways involved cell death, survival, movement, and OX40 signalling.

Discussion {#s3}
==========

This is the first GWAS meta-analysis investigating the genetics of TPOAbs in the normal population in up to 18,297 individuals from 11 populations with replication in up to 8,990 individuals from 5 populations. We identified 5 GWAS significant loci associated with TPOAb-positivity and/or levels.

The most significant hit for both TPOAb-positivity and TPOAb levels was located near the *TPO* gene itself. TPO is a membrane-bound protein located on the apical membranes of the thyroid follicular cell, catalyzing key reactions in thyroid hormone synthesis [@pgen.1004123-Ruf1]. Mutations in *TPO* have been found in patients with congenital hypothyroidism [@pgen.1004123-Bakker1], [@pgen.1004123-Bikker1]. Although TPOAbs are valid clinical biomarkers of AITD, they are generally considered to be secondary to the thyroid damage inflicted by T-cells.

The *FOXE1* gene has been previously associated with hypothyroidism [@pgen.1004123-Denny1], [@pgen.1004123-Eriksson1] and is known to regulate transcription of *TPO* [@pgen.1004123-Ortiz1]. In this context it is interesting to note that we did not find any associations of the variant near *TPO* with hypothyroidism. Most genes that have been associated with AITD (predominantly Graves\' disease) by candidate gene and GWAS studies so far are located in the HLA class I and II regions, or in genes involved in T-cell (i.e., *CTLA-4*, *PTPN22*) or other autoimmune responses [@pgen.1004123-Weetman2], [@pgen.1004123-Simmonds2]. Until now, the *TPO* gene itself had not been associated with AITD, except in one recent candidate gene analysis in a small cohort (n = 188) without replication [@pgen.1004123-Faam1]. A variant near *TPO* (rs11694732), which is in LD with rs11675434 (r2 = 0.97 in HapMap2), has previously been associated with TSH levels by Gudmundsson et al [@pgen.1004123-Gudmundsson1]. However, various other GWAS on serum TSH and FT4 levels have not found any significant associations in or near this locus, including a recent similar sized GWAS by Porcu et al [@pgen.1004123-Porcu1].

Three of the other four loci identified here are located in or are in linkage disequilibrium (LD) with genes previously associated with other autoimmune diseases. Rs1230666 is located in intron 9 of *MAGI3*, encoding a protein that modulates activity of AKT/PKB. AKT/PKB is expressed in the thyroid and regulates apoptosis [@pgen.1004123-Wu1], which seems to play an important role in the development of AITD [@pgen.1004123-Bossowski1], [@pgen.1004123-Wang1]. In addition, rs1230666 is in LD with rs2476601 (r2 = 0.70 in HapMap2), a variant causing a R620W substitution in *PTPN22*. PTPN22 is a lymphoid-specific intracellular phosphatase involved in the T-cell receptor signaling pathway. Variations in *PTPN22*, and specifically R620W, are associated with various autoimmune disorders including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and Graves\' disease [@pgen.1004123-Barrett1], [@pgen.1004123-Orru1], [@pgen.1004123-Raychaudhuri2], [@pgen.1004123-Velaga1]. The associations of the *MAGI3* locus with TPOAb-positivity and Graves\' disease may therefore also be explained by linkage with disease-associated variants in *PTPN22* [@pgen.1004123-Steer1]. Of note, the association signal at rs2476601 is one order weaker than that of the top variant rs1230666.

The *BACH2* locus has been implicated in the susceptibility to several autoimmune diseases, including celiac disease, type 1 diabetes, vitiligo, Crohn\'s disease, and multiple sclerosis [@pgen.1004123-Barrett1], [@pgen.1004123-Dubois1], [@pgen.1004123-Franke1], [@pgen.1004123-Jin1], [@pgen.1004123-Sawcer1]. A recent candidate gene analysis associated the *BACH2* locus with an increased risk of AITD, including Hashimoto\'s thyroiditis and Graves\' disease [@pgen.1004123-Cooper1]. However, the associations were not significant when Hashimoto\'s thyroiditis and Graves\' disease were studied separately. *BACH2* is specifically expressed in early stages of B-cell differentiation and represses different immunoglobulin genes [@pgen.1004123-Muto1]. Interestingly, BACH2 can bind to the co-repressor SMRT (silencing mediator of retinoid and thyroid receptor), which may suggest a more direct effect on thyroid hormone secretion and action as well.

Polymorphisms in *ATXN2* have been associated with multiple neurodegenerative diseases, including spinocerebellar ataxia and Parkinson\'s disease [@pgen.1004123-Houlden1], [@pgen.1004123-Liu1], [@pgen.1004123-Magana1]. Different epidemiological studies have associated thyroid dysfunction with cerebellar ataxia [@pgen.1004123-Bonuccelli1], [@pgen.1004123-Tandeter1]. Furthermore, the identified SNP in *ATXN2* has been previously associated with renal function, serum urate levels and blood pressure [@pgen.1004123-Kottgen1], [@pgen.1004123-Kottgen2], [@pgen.1004123-Wain1]. However, this SNP is in high LD with rs3184504 (r2 = 0.873), a variant causing a Trp262Arg substitution of *SH2B adaptor protein 3* (*SH2B3)*. *SH2B3* encodes the adaptor protein LNK, a key negative regulator of cytokine signaling playing a critical role in hematopoiesis. This variant is associated with susceptibility to several autoimmune diseases, including celiac disease, type 1 diabetes, vitiligo, and rheumatoid arthritis [@pgen.1004123-Barrett1], [@pgen.1004123-Dubois1], [@pgen.1004123-Jin1], [@pgen.1004123-Stahl1], suggesting more relevance for TPOAb levels than ATXN2. This is supported by a recent study which showed that variants in LD with *SH2B3*, *BACH2*, and *PTPN22* are associated with TPOAb levels in patients with type 1 diabetes [@pgen.1004123-Plagnol1].

Whereas the above four loci are located in genes involved in the immune response or the autoantigen, the *KALRN* (*Kalirin*) gene encodes a multi-domain guanine nucleotide exchange factor for GTP-binding proteins of the Rho family. The relation of *KALRN* with levels of TPOAbs is unclear. This gene has recently been found to be associated with megakaryopoiesis and platelet formation [@pgen.1004123-Gieger1], which may suggest a function in the immune system [@pgen.1004123-Knaus1]. We furthermore performed pathway analyses on the stage 1 TPOAb-positivity and TPOAb level lead SNPs, and identified the cell death, survival and movement pathway as an important pathway for TPOAbs. This finding is supported by previous studies, which show an important role for apoptosis in the development of AITD [@pgen.1004123-Bossowski1], [@pgen.1004123-Wang1]. Another top pathway involved was the OX40 signalling pathway, and it is of interest to note that OX40 is a T-cell activator promoting the survival of CD4+ T-cells at sites of inflammation [@pgen.1004123-Gramaglia1].

Our results have potential clinical relevance for several reasons. Genetic risk scores based on these novel common (risk allele frequencies: 9--40%) TPOAb-associated SNPs enabled us to identify a large subgroup in the general population with a two-fold increased risk of TPOAb-positivity (10.4% vs 5.4%). These individuals also have a higher risk of increased TSH levels and a lower risk of goiter, suggesting an advanced stage of destruction of the thyroid due to autoimmune processes. Furthermore, pregnant women with high genetic risk scores had a 2.4 times increased risk of TPOAb-positivity during pregnancy. In this context it is interesting to note that TPOAb-positive pregnant women have an increased risk of miscarriages and preterm births independent of thyroid function [@pgen.1004123-Thangaratinam1].

Associations with thyroid disease were also found on an individual SNP level. The *MAGI3* SNP was associated with a substantially increased risk of hypothyroidism, and the *BACH2* SNP showed a borderline significant association (*P* = 0.011) with a higher risk of increased TSH levels, which includes subjects with subclinical and overt hypothyroidism. Furthermore, both loci were significantly associated with an increased risk of Graves\' hyperthyroidism in an independent population. To predict which patients with first or second degree relatives with documented Hashimoto\'s or Graves\' disease will develop clinical thyroid disease, a clinical algorithm has been developed (i.e., the THEA score) [@pgen.1004123-Strieder2]. Future studies should analyze if these genetic markers increase the sensitivity of the THEA score. Graves\' hyperthyroidism and Hashimoto\'s thyroiditis co-segregate in families and subjects with TPOAbs have an increased risk of both diseases [@pgen.1004123-Strieder1], [@pgen.1004123-Strieder2], [@pgen.1004123-Brix2], [@pgen.1004123-Tomer1], [@pgen.1004123-Kordonouri1], [@pgen.1004123-Vanderpump1]. The current study provides insight into this phenomenon by showing that specific loci associated with TPOAbs and (subclinical) hypothyroidism, *i.e. MAGI3* and *BACH2*, are also associated with Graves\' hyperthyroidism in an independent case-control study.

The prevalence of TPOAb-positivity in the general population is high (5--24%), but it is currently unknown why part of the individuals with thyroid autoimmunity develop clinical thyroid disease whereas others do not [@pgen.1004123-Hollowell1], [@pgen.1004123-Weetman2]. In this context it is interesting to note that the TPOAb-associated SNPs located in *TPO* and *ATXN2* were not associated with clinical thyroid disease. This suggests that the TPOAbs in these individuals may be of less clinical relevance, providing insight into why TPOAb-positive individuals do or do not eventually develop clinical thyroid disease.

Our study has some limitations. The validity of the results is restricted to individuals from populations of European ancestry. Future GWASs in populations from non-European descent will be required to determine to which extent our results can be generalized to other ethnic groups. Secondly, we did not perform conditional analyses to further identify secondary association signals within the identified loci, nor did we perform functional studies for the identified variants. Further research is therefore needed to unravel the exact biological mechanism behind the observed associations. The fact that various TPOAb assays were used across the participating cohorts could lead to bias. We therefore used TPOAb-positivity cut-off values as provided by the respective assay manufacturer, instead of using one fixed cut-off value. This is also of clinical importance as in clinical practice most institutions rely on the TPOAb-positivity cut-off as provided by the assay manufacturer. Furthermore, we did not detect heterogeneity in our results, supporting the fact that results obtained with different assays can be combined across cohorts using the z-score based meta-analysis. Finally, as AITD coincides with other autoimmune diseases, our results could be driven by indirect associations with other autoimmune diseases. However, AITD is the most common autoimmune disease in the general population. We furthermore show that carriage of multiple risk alleles is associated with an increased risk of thyroid dysfunction, which underlines the clinical importance of our findings.

In conclusion, this first GWAS for TPOAbs identified five newly associated loci, three of which were also associated with clinical thyroid disease. Furthermore, we show that carriage of multiple risk variants is not only associated with a substantial increased risk of TPOAb-positivity, but also with a higher risk of increased TSH levels (including subclinical and overt hypothyroidism) and a lower risk of goiter. These genetic markers not only help to identify large groups in the general population with an increased risk of TPOAb-positivity, but may also predict which TPOAb-positive persons are particularly at risk of developing clinical thyroid disease.

Materials and Methods {#s4}
=====================

Study cohorts {#s4a}
-------------

For the TPOAb GWAS stage 1 and 2 analyses, and the hypothyroidism, hyperthyroidism and goiter analyses, individuals were recruited from 16 independent community-based and family studies. For the Graves\' disease analyses, cases were recruited from the United Kingdom Graves\' disease cohort and controls from the British 1958 Birth Cohort. Thyroid cancer cases and controls were recruited from the Nijmegen and Ohio thyroid cancer cohorts. A detailed description of the original cohorts contributing samples is provided in [Table 1](#pgen-1004123-t001){ref-type="table"} and in the Supplementary Material. All participants provided written informed consent and protocols were approved by the institutional review boards or research ethics committees at the respective institutions, and conducted according to the Declaration of Helsinki.

Phenotype definitions {#s4b}
---------------------

Serum TPOAb levels were determined with a range of assays. TPOAb-positives were defined as subjects with TPOAb levels above the assay-specific TPOAb-positivity cut-off, as defined by the manufacturer ([Table 1](#pgen-1004123-t001){ref-type="table"}). Serum TSH and free thyroxine (FT4) levels were determined using a range of assays ([Table 1](#pgen-1004123-t001){ref-type="table"}). Assay-specific TSH and FT4 reference ranges were used, as provided by the manufacturer ([Table 1](#pgen-1004123-t001){ref-type="table"}). Overt hypothyroidism was defined as a high TSH (i.e., a TSH level above the TSH reference range) and a low FT4. Increased TSH was defined as a high TSH, including persons with overt hypothyroidism or subclinical hypothyroidism (i.e., high TSH with a normal FT4). Overt hyperthyroidism was defined as a low TSH and a high FT4. Decreased TSH was defined as a low TSH, including persons with subclinical or overt hyperthyroidism.

The diagnosis of goiter is described in the Supplementary Material, and the diagnosis of Graves\' disease and thyroid cancer in the respective cohorts have been described previously [@pgen.1004123-Gudmundsson1].

Genotyping {#s4c}
----------

Samples were genotyped with a range of GWAS genotyping arrays (Supplementary [Table S1](#pgen.1004123.s007){ref-type="supplementary-material"}). Sample and SNP quality control procedures were undertaken within each study. For each GWAS, over 2.5 million SNPs were imputed using CEU samples from Phase 2 of the International HapMap project ([www.hapmap.org](http://www.hapmap.org)). Genotyping procedures in the stage 2, Graves\' disease and thyroid cancer populations are described in the Supplementary Material.

Association analyses {#s4d}
--------------------

The heritabilities of TPOAb-positivity and serum TPOAb levels were estimated, as described in the Supplementary Material.

In stage 1, we performed a GWAS on TPOAb-positivity as well as a GWAS on continuous TPOAb levels. Persons taking thyroid medication were excluded. Each SNP was tested for association with TPOAb-positivity using logistic regression analyses, adjusting for age and sex. For cohorts with family structure, we approximated the probability of being affected with a linear mixed model adjusting for age and sex. The produced model was used to predict the expected proportion of "risk" (effective) alleles in cases and controls, hence giving the means to estimate odds ratios. Only unrelated individuals were considered for the SardiNIA cohort. For the GWAS of continuous TPOAb levels, samples with a TPOAb level lower than the minimum TPOAb assay detection limit ([Table 1](#pgen-1004123-t001){ref-type="table"}) were excluded. TPOAb levels were natural log-transformed, and sex-specific, age adjusted standardized residuals were calculated. Each SNP was tested for association with these TPOAb level residuals using linear regression analyses (additive model), correcting for relatedness in studies with family structure. See Supplementary [Table S1](#pgen.1004123.s007){ref-type="supplementary-material"} for the software used for these analyses.

Before meta-analysis, SNPs with a minor allele frequency (MAF) \<1% or a low imputation quality were excluded (Supplementary Material), after which the results of each GWAS were combined in a population size weighted z-score based meta-analysis using METAL [@pgen.1004123-Willer1]. Genomic control was applied to individual studies if λ\>1.0.

In stage 2, we followed-up stage 1 GWAS significant SNPs, as well as promising SNPs not reaching GWAS significance, in an attempt to reach GWAS significant associations by increasing sample size (Supplementary Material). Results from stage 1 and 2 were combined in a population size weighted z-score based meta-analysis using METAL [@pgen.1004123-Willer1]. A z-score based meta-analysis was used to reduce bias that might be induced by different assays. As this method does not provide betas, and we wanted to provide a rough estimate of the actual effect sizes for convenience, we calculated betas using the fixed effects (inverse variance based) meta-analysis method. Heterogeneity was tested, applying bonferroni based *P*-value thresholds of *P* = 0.004 for the TPOAb-positivity analyses and *P* = 0.005 for the TPOAb level analyses.

All studies assessed and, if present, corrected for population stratification using principal-component analysis (PCA) and/or multidimensional-scaling (MDS), with the exception of SardiNIA and ValBorbera where the high isolation substantiates a lack of stratification ([Table S1](#pgen.1004123.s007){ref-type="supplementary-material"}) [@pgen.1004123-Milani1], [@pgen.1004123-Pilia1]. Lambda values were all ∼1, indicating that population stratification was overall properly accounted for ([Table S1](#pgen.1004123.s007){ref-type="supplementary-material"}). To fully remove residual effects, we applied genomic correction to studies were lambda was \>1. The final meta-analyses reported a lambda of 1.01 for both the TPOAb-positivity and the TPOAb level GWAS, thus no genomic correction was applied.

The variances explained by the GWAS significant SNPs were calculated. We subsequently studied the individual as well as the combined effects of the GWAS significant SNPs on the risk of clinical thyroid disease, as specified in the Supplementary Material. In short, to study combined effects, a genetic risk score was calculated for every person as the weighted sum of TPOAb risk alleles. The associations between the individual SNPs, genetic risk scores and the risk of abnormal thyroid function tests were studied using logistic regression analyses. Logistic regression analyses were used to study the associations with goiter, Graves\' disease and thyroid cancer (Supplementary Material). The results of each study were combined in a population size weighted z-score based meta-analysis using METAL [@pgen.1004123-Willer1].

Various bioinformatic tools were searched for evidence for functional relevance of the GWAS significant SNPs and pathway analyses were performed on the Stage 1 lead SNPs (see Supplementary Material).

Supporting Information {#s5}
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TPOAb level distributions in persons with detectable TPOAb levels in stage 1 and 2 populations.
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Click here for additional data file.
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Quantile-quantile (QQ) plots for the TPOAb-positivity and TPOAb level stage 1 meta-analyses.
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Click here for additional data file.

###### 

Manhattan plots for stage 1 meta-analyses for TPOAb-positivity (a) and TPOAb levels (b). SNPs are plotted on the x-axis according to their chromosomal position against TPOAb-positivity (a) or TPOAb levels (b) (shown as -- log~10~ *P* value) on the y-axis. The horizontal grey line indicates the threshold for genome-wide statistical significance (*P*\<5×10^−8^). Genome-wide significant associations were observed near *TPO* (Chr 2p25; *P* = 1.5×10^−12^), at *ATXN2* (Chr 12q24.1; *P* = 1.6×10^−9^) and near *HCP5* (Chr 6p21.3; *P* = 4.1×10^−8^) for TPOAb-positivity, and near *TPO* (Chr 2p25; *P* = 5.4×10^−13^) and at *ATXN2* (Chr 12q24.1; *P* = 1.1×10^−8^) for TPOAb levels.
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Regional association plots of stage 1 lead loci for TPOAb-positivity (panels a-m). The y-axis on the left indicates the -- log~10~ *P* value for the association with TPOAb --positivity. SNPs are plotted on the x-axis according to their chromosomal position. The most significant stage 1 SNP is indicated in purple. The combined stage 1 and 2 result of this SNP is indicated in yellow. The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP. Symbols reflect functional genomic annotation, as indicated in the legend. The blue y-axes on the right of each plot indicate the estimated recombination rates (based on HapMap Phase II); the bottom of each panel shows the respective annotated genes at the locus and their transcriptional direction. Mb, megabases.
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Regional association plots of stage 1 lead loci for TPOAb levels (panels a-j). The y-axis on the left indicates the -- log~10~ *P* value for the association with TPOAb levels. SNPs are plotted on the x-axis according to their chromosomal position. The most significant stage 1 SNP is indicated in purple. The combined stage 1 and 2 result of this SNP is indicated in yellow. The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP. Symbols reflect functional genomic annotation, as indicated in the legend. The blue y-axes on the right of each plot indicate the estimated recombination rates (based on HapMap Phase II); the bottom of each panel shows the respective annotated genes at the locus and their transcriptional direction. Mb, megabases.
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GRAIL results for the stage 1 TPOAb-positivity and TPOAb level lead SNPs. GRAIL circle plot of locus connectivity where each locus is plotted in a circle, where significant connections (*P*\<0.05) based on PubMed abstracts are drawn spanning the circle. Analyses were based on the 20 stage 1 TPOAb-positivity and TPOAb level lead SNPs.
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Study sample genotyping, quality control and association analyses for stage 1 populations.
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Associations of stage 1 lead SNPs with TPOAb-positivity in stage 1 and 2.
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Associations of stage 1 lead SNPs with serum TPOAb levels in stage 1 and 2.
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Stage 1 TPOAb-positivity and TPOAb level meta-analyses results for GWAS significant SNPs reported in previous GWAS on thyroid related phenotypes.
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Genetic risk score and the risk of increased TSH levels.
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Newly identified TPOAb associated loci and the risk of thyroid cancer.
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Top IPA associated networks for the Stage 1 TPOAb-positivity and TPOAb level lead SNPs.
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Top IPA associated canonical pathways for the Stage 1 TPOAb-positivity and TPOAb level lead SNPs.
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Supplementary methods.
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